Patient perception and satisfaction with immunoglobulin therapy: A comparative analysis of intravenous Ig (IVIg) and subcutaneous Ig (SCIg)

Authors: Christine Miller, PharmD; Derrek Blake, RN, BSN, IgCN; Barbara Prosser, RPh – Soleo Health

Introduction

A therapy satisfaction questionnaire was developed by this national complex specialty pharmacy to capture patients’ perception of immunoglobulin (Ig) therapy. The questionnaire assesses patient satisfaction with their current Ig therapy and identifies barriers to care throughout the patient journey. Administered every 90 days, patients have the option to decline participation. The purpose of this study is to identify trends in responses among patients receiving Ig therapy for immunology conditions and to compare differences, if any, between intravenous Ig (IVIg) and subcutaneous Ig (SCIg).

Methods

A retrospective review of medical records was conducted for patients receiving Ig therapy for immunology indications between January 1, 2023, and December 31, 2023. Aggregate responses from the therapy satisfaction questionnaire were collected and analyzed across all Ig therapies. The patient population was then divided into IVIg and SCIg groups, and the results were compared.

Results

Discussion

This study provides an aggregate view of Ig therapy satisfaction for immunology diagnoses. Future research could explore therapy satisfaction responses in patients receiving Ig therapy for neurology indications, particularly considering higher doses of Ig are often used in neurologic conditions.

Conclusion

Overall, patients expressed a positive perception of Ig therapy for immunology conditions. The majority agree that Ig therapy is effective and worthwhile, with some differences observed between the IVIg population and SCIg population. A higher proportion of SCIg patients strongly agree Ig therapy is effective and worth their time than patients who receive IVIg. Patients do not view Ig therapy as a burden. While some barriers exist, such as financial, administration, and scheduling challenges, most patients did not report any barriers at the time of questionnaire completion.

Authors of this presentation disclose the following concerning possible financial or personal relationships with commercial entities that may have a direct or indirect interest in the subject matter of this presentation: Nothing to disclose.

Originally presented at IgNS 2024 National Conference

© 2024 Soleo Health Inc. All Rights Reserved